Information  X 
Enter a valid email address

Company Name matching 'Junshi Biosciences'

Date
Time Source
Company
Announcement
10 Jan 2022 1:58 pm GNW   Junshi Biosciences Junshi Biosciences and Coherus Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
05 Jan 2022 11:00 am GNW   Junshi Biosciences Junshi Biosciences and DotBio Announce Collaboration to Develop Next-Generation Antibody Therapy with DotBody Module
13 Dec 2021 12:00 pm GNW   Junshi Biosciences Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
10 Dec 2021 2:43 pm GNW   Junshi Biosciences Junshi Biosciences Announces NMPA Accepted supplemental New Drug Application for Toripalimab in Combination with Chemotherapy as First-Line Treatment of Advanced NSCLC
05 Dec 2021 11:06 pm GNW   Junshi Biosciences Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12
03 Dec 2021 12:53 pm GNW   Junshi Biosciences Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China’s National Reimbursement Drug List
30 Nov 2021 1:00 am GNW   Junshi Biosciences Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma
15 Nov 2021 1:30 pm GNW   Junshi Biosciences Junshi Biosciences and Coherus Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer
01 Nov 2021 12:00 pm GNW   Junshi Biosciences TopAlliance Appoints Virginia Ellen Maher, MD, as Vice President of Medical Sciences
  11:30 am GNW   Junshi Biosciences Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
19 Sep 2021 12:29 pm GNW   Junshi Biosciences Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19
17 Sep 2021 1:19 am GNW   Junshi Biosciences Junshi Biosciences and Coherus to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
15 Sep 2021 1:30 pm GNW   Junshi Biosciences Junshi Biosciences and Coherus Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine
14 Sep 2021 1:55 am GNW   Junshi Biosciences Positive Interim Results of CHOICE-01 Study Evaluating Junshi Biosciences and Coherus’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
01 Sep 2021 1:00 pm GNW   Junshi Biosciences Junshi Biosciences and Coherus Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
31 Aug 2021 12:30 am GNW   Junshi Biosciences Junshi Biosciences Announces 2021 Interim Financial Results and Provides Corporate Updates
29 Aug 2021 1:03 pm GNW   Junshi Biosciences Distribution of Etesevimab/JS016 in the US Reopened
27 Aug 2021 12:30 am GNW   Junshi Biosciences Junshi Biosciences Announces Acceptance by NMPA of Investigational New Drug Application for the Subcutaneous Injection of Anti-BLyS Monoclonal Antibody
19 Aug 2021 2:09 am GNW   Junshi Biosciences Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
12 Aug 2021 1:01 pm GNW   Junshi Biosciences Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
30 Jul 2021 1:40 am GNW   Junshi Biosciences Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
20 Jul 2021 1:41 am GNW   Junshi Biosciences Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines
  1:41 am GNW   Junshi Biosciences Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines
02 Jul 2021 2:09 am GNW   Junshi Biosciences Junshi Biosciences Appoints Wei Qian as Chief Commerical Officer
28 Jun 2021 3:22 pm GNW   Junshi Biosciences Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014
04 Jun 2021 1:45 am GNW   Junshi Biosciences Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
29 Apr 2021 12:30 pm GNW   Junshi Biosciences Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting
22 Apr 2021 1:42 pm GNW   Junshi Biosciences Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study
12 Apr 2021 1:00 pm GNW   Junshi Biosciences NMPA Approves Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma who Failed Platinum-Containing Chemotherapy or Progressed within 12 Months of Neoadjuvant or Adjuvant Platinum-Containing Chemotherapy
30 Mar 2021 3:04 pm GNW   Junshi Biosciences Junshi Biosciences Announces Full Year 2020 Financial Results And Provides Corporate Updates
03 Mar 2021 11:45 am GNW   Junshi Biosciences Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma
01 Mar 2021 1:15 am GNW   Junshi Biosciences Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China
26 Feb 2021 5:35 pm GNW   Junshi Biosciences U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy
21 Feb 2021 11:00 pm GNW   Junshi Biosciences NMPA Approves Toripalimab in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma after Failure of at Least Two Lines of Prior Systemic Therapy
19 Feb 2021 2:18 am GNW   Junshi Biosciences Junshi Biosciences Announces Acceptance by the NMPA of Supplemental New Drug Application for Toripalimab Combined with Chemotherapy for The First-Line Treatment of Nasopharyngeal Carcinoma
10 Feb 2021 7:45 am GNW   Junshi Biosciences Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19
01 Feb 2021 12:53 pm GNW   Junshi Biosciences Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada
26 Jan 2021 3:35 pm GNW   Junshi Biosciences New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent
25 Jan 2021 12:07 am GNW   Junshi Biosciences FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
29 Dec 2020 1:22 am GNW   Junshi Biosciences Junshi Biosciences Announces Inclusion of Toripalimab in The China National Reimbursement Drug List
14 Dec 2020 12:00 am GNW   Junshi Biosciences CHOICE-01 Phase III Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival at the First-Line Treatment of Advanced NSCLC
01 Dec 2020 5:13 am GNW   Junshi Biosciences Junshi Biosciences Announces Dosing of First Patient in Phase I Study of Anti-TROP2 Antibody -TUB196 Conjugate
30 Nov 2020 11:54 pm GNW   Junshi Biosciences Junshi Biosciences Announces Acceptance by NMPA of its IND Application for JS006
08 Oct 2020 3:50 am GNW   Junshi Biosciences Combination Study with JS016 and LY-CoV555 for Patients with Mild-to-Moderate COVID-19 Symptoms Met Primary and Secondary Endpoints
17 Sep 2020 11:00 pm GNW   Junshi Biosciences Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab for the Treatment of Soft Tissue Sarcoma
16 Sep 2020 5:45 pm GNW   Junshi Biosciences Junshi Biosciences and Wigen Biomedicine Enter Global Development and Commercialization Collaboration for Four Small Molecule Cancer Drug Candidates
11 Sep 2020 1:36 am GNW   Junshi Biosciences Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
31 Aug 2020 1:00 am GNW   Junshi Biosciences Junshi Biosciences Announces Financial Results for Six Months Ended June 30, 2020 and Provides Corporate Updates
20 Aug 2020 3:45 pm GNW   Junshi Biosciences Junshi Biosciences and Impact Therapeutics Establish Joint Venture to Develop PARP Inhibitor Senaparib (IMP4297) in China
10 Aug 2020 3:07 am GNW   Junshi Biosciences TopAlliance Appoints Patricia Keegan, M.D., as Chief Medical Officer
13 Jul 2020 1:00 am GNW   Junshi Biosciences Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 in China
12 Jul 2020 1:20 pm GNW   Junshi Biosciences Junshi Biosciences Announces Approval of “B” Marker Removal from Company’s Stock Name by HKEX
04 May 2020 2:14 pm GNW   Junshi Biosciences Junshi Biosciences and Lilly to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19
30 Apr 2020 3:56 pm GNW   Junshi Biosciences Junshi Biosciences Announces Acceptance of a Supplemental NDA in China for Toripalimab in Advanced Nasopharyngeal Carcinoma
30 Mar 2020 5:43 pm GNW   Junshi Biosciences Junshi Biosciences Announces Full-Year 2019 Financial Results and Business Updates
  5:30 pm GNW   Junshi Biosciences Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab in Combination with Pfizer’s Axitinib for the Treatment of Mucosal Melanoma
20 Mar 2020 4:15 pm GNW   Junshi Biosciences Junshi Biosciences Announces Co-Development Agreement with IMCAS to Advance Neutralizing Antibodies as Potential Novel Treatment for COVID-19
02 Mar 2020 7:20 pm GNW   Junshi Biosciences Junshi Biosciences Reports Key 2019 Financial Results


Company Announcements Archive »


a d v e r t i s e m e n t